

Dear Editor,

We submit a revised version of our invited editorial titled “The role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus”, Manuscript ID 54009, for consideration for publication in the World Journal of Diabetes. We thank the Reviewers for their comments, which improved our manuscript. We modified our review accordingly. All changes are shown in red in the revised text. This is an invited editorial and the invited manuscript ID is 00036318.

Response to Reviewers' comments:

Reviewer number ID: 00504545

This editorial is clear and with a great clinical interest for patients with DM and HF using SGLT2 for the prevention and treatment of this complication. Really it is convenient to do wide clinical trials for these affected patients because it looks a very promising treatment reducing the related mortality with this complication.

**We thank this Reviewer for these positive comments.**

Reviewer number ID : 02894577

The editorial focused on the role of SGLT2i in the management of heart failure in patients with diabetes mellitus. The issue is of interest, considering diabetes the risk of the heart failure.

**We thank this Reviewer for stating “The issue is of interest”.**

I have a few issues that deserve an answer.

1. In the first sentence of the instruction, please update the new the prevalence of diabetes mellitus.

**We now mention “During the last decades, the prevalence of diabetes mellitus (DM) worldwide has almost doubled, from 4.7% in 1984 to 9.3% in 2019” and we cite a recent paper.**

2. It is better to compare the results of CV outcome in the EMPA-REG OUTCOME, CANVAS and DAPA-HF trials.

**We now mention the results of CV outcome in the EMPA-REG OUTCOME, CANVAS and DAPA-HF trials.**

3. What is the potential mechanism of these beneficial effects besides glucose-lowering effect.

**We now mention “Other actions of SGLT2 inhibitors besides glucose-lowering might play a role in the beneficial effects of these agents in patients with HF. Indeed, it has been reported that SGLT2 inhibitors promote reverse cardiac remodeling, improve myocardial energetics and filling conditions, reduce LV wall stress and mass and reduce blood pressure and arterial stiffness<sup>[40-43]</sup>.”**

We look forward to your decision.

Best regards,

Konstantinos Tziomalos, MD, PhD

Associate Professor of Internal Medicine

Medical School, Aristotle University of Thessaloniki, Greece